The 1 analysts offering 12-month price forecasts for Protagenic Therapeutics Inc have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 16.00. The median estimate represents a +798.88% increase from the last price of 1.78.
The current consensus among 1 polled investment analysts is to Buy stock in Protagenic Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.20
Reporting Date Apr 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.